Bromocriptine suppresses ACTH secretion from human pituitary tumour cells in culture by a dopaminergic mechanism.
Bromocriptine (0.13-13 microM) significantly inhibited ACTH secretion in a dose-dependent manner when added to cell cultures of a human corticotrophic adenoma for 24 h. Haloperidol (13 microM), but not serotonin (13 microM), blocked this inhibition but had no significant effect when added alone. In addition, dopamine (10 microM) reduced ACTH secretion during a 4-h incubation, whereas serotonin (0.01-10 microM) was ineffective. An ectopic ACTH secreting lung carcinoid was non-responsive to doses of bromocriptine up to 13 microM. These results demonstrate a direct suppressive action of bromocriptine on a human pituitary corticotrophic adenoma through dopaminergic rather than serotoninergic mechanisms.
D000236:Adenoma / Q000378:metabolism* / Q000473:pathology; D000324:Adrenocorticotropic Hormone / Q000378:metabolism*; D000328:Adult; D001971:Bromocriptine / Q000494:pharmacology*; D002276:Carcinoid Tumor / Q000378:metabolism; D002478:Cells, Cultured; D004298:Dopamine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism; D008297:Male; D010911:Pituitary Neoplasms / Q000378:metabolism* / Q000473:pathology
D001971:Bromocriptine; D000324:Adrenocorticotropic Hormone; D006220:Haloperidol; D004298:Dopamine